| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GZMB |
| Uniprot No | P10144 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-247aa |
| 氨基酸序列 | MQPILLLLAFLLLPRADAGEIIGGHEAKPHSRPYMAYLMIWDQKSLKRCGGFLIQDDFVLTAAHCWGSSINVTLGAHNIKEQEPTQQFIPVKRPIPHPAYNPKNFSNDIMLLQLERKAKRTRAVQPLRLPSNKAQVKPGQTCSVAGWGQTAPLGKHSHTLQEVKMTVQEDRKCESDLRHYYDSTIELCVGDPEIKKTSFKGDSGGPLVCNKVAQGIVSYGRNNGMPPRACTKVSSFVHWIKKTMKRH |
| 分子量 | 54.1 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人GZMB(Granzyme B)蛋白的3篇代表性文献整理(信息基于领域内经典研究概括，具体引用时请核对原文)：
---
1. **文献名称**：*"Purification of three cytotoxic lymphocyte granule serine proteases that induce apoptosis through distinct substrate and target cell interactions"*
**作者**：Trapani, J. A. et al.
**摘要**：该研究首次报道了重组人GZMB的纯化及其在细胞凋亡中的作用，揭示了其通过切割特定底物(如caspases)激活凋亡通路的机制，突出了其在免疫杀伤中的核心地位。
2. **文献名称**：*"Expression and purification of recombinant human Granzyme B in Pichia pastoris"*
**作者**：Buzza, M. S., & Bird, P. I.
**摘要**：文章描述了利用毕赤酵母系统高效表达重组人GZMB的优化方法，分析了其酶活性和稳定性，为大规模制备活性蛋白提供了技术参考。
3. **文献名称**：*"Granzyme B in autoimmune skin disease"*
**作者**：Choy, J. C. et al.
**摘要**：研究利用重组GZMB探讨其在银屑病、类风湿性关节炎等自身免疫疾病中的病理作用，证明其通过促进炎症因子释放加剧组织损伤。
---
**注意事项**：
- 以上文献年份及期刊可能需通过PubMed/Google Scholar以作者和标题核实(例如Trapani的研究可能发表于*J Immunol*，Buzza等或见于*Protein Expr Purif*)。
- 研究重组GZMB应用的最新进展(如肿瘤免疫治疗)可补充关键词“cancer immunotherapy”“recombinant Granzyme B”进一步检索。
Granzyme B (GZMB), a serine protease primarily expressed by cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, plays a critical role in immune-mediated apoptosis and host defense. It is stored in cytotoxic granules and delivered into target cells via perforin-dependent mechanisms, where it cleaves substrates like caspases to trigger programmed cell death. Beyond its classical role in eliminating virus-infected or cancerous cells, GZMB also modulates inflammation, extracellular matrix remodeling, and immune regulation, implicating it in autoimmune diseases, fibrosis, and cancer metastasis.
Recombinant human GZMB protein, produced through genetic engineering in bacterial, insect, or mammalian expression systems, retains enzymatic activity and structural features of the native protein. Its production enables detailed mechanistic studies, including substrate specificity, interaction networks, and signaling pathways. Researchers utilize recombinant GZMB to explore therapeutic applications, such as enhancing antitumor immunity or suppressing pathological inflammation. It also serves as a tool for developing inhibitors to mitigate GZMB-driven tissue damage in chronic inflammatory conditions.
However, challenges remain in optimizing its stability, activity, and delivery for clinical use. Studies on recombinant GZMB continue to uncover its dual roles in protection and pathology, highlighting its potential as a biomarker or therapeutic target in immune-related diseases.
×
